volume 39 issue 12 publication number 240

Niosomes: a novel targeted drug delivery system for cancer

Maryam Moghtaderi 1
Kamand Sedaghatnia 2
Mahsa Bourbour 3
Mahdi Fatemizadeh 4
Zahra Salehi Moghaddam 5
Faranak Hejabi 6
Fatemeh Heidari 7
Sameer Quazi 8, 9, 10
Bahareh Farasati Far 11
Publication typeJournal Article
Publication date2022-09-29
scimago Q1
wos Q2
SJR0.916
CiteScore5.3
Impact factor3.5
ISSN13570560, 1559131X
Cancer Research
Oncology
General Medicine
Hematology
Abstract
Recently, nanotechnology is involved in various fields of science, of which medicine is one of the most obvious. The use of nanoparticles in the process of treating and diagnosing diseases has created a novel way of therapeutic strategies with effective mechanisms of action. Also, due to the remarkable progress of personalized medicine, the effort is to reduce the side effects of treatment paths as much as possible and to provide targeted treatments. Therefore, the targeted delivery of drugs is important in different diseases, especially in patients who receive combined drugs, because the delivery of different drug structures requires different systems so that there is no change in the drug and its effectiveness. Niosomes are polymeric nanoparticles that show favorable characteristics in drug delivery. In addition to biocompatibility and high absorption, these nanoparticles also provide the possibility of reducing the drug dosage and targeting the release of drugs, as well as the delivery of both hydrophilic and lipophilic drugs by Niosome vesicles. Since various factors such as components, preparation, and optimization methods are effective in the size and formation of niosomal structures, in this review, the characteristics related to niosome vesicles were first examined and then the in silico tools for designing, prediction, and optimization were explained. Finally, anticancer drugs delivered by niosomes were compared and discussed to be a suitable model for designing therapeutic strategies. In this research, it has been tried to examine all the aspects required for drug delivery engineering using niosomes and finally, by presenting clinical examples of the use of these nanocarriers in cancer, its clinical characteristics were also expressed.
Found 
Found 

Top-30

Journals

1
2
3
4
5
Pharmaceutics
5 publications, 6.02%
Pharmaceuticals
4 publications, 4.82%
International Journal of Pharmaceutics
3 publications, 3.61%
Biomedicine and Pharmacotherapy
3 publications, 3.61%
Journal of Drug Delivery Science and Technology
3 publications, 3.61%
BioNanoScience
3 publications, 3.61%
Medical Oncology
2 publications, 2.41%
International Journal of Molecular Sciences
2 publications, 2.41%
Materials Today Bio
2 publications, 2.41%
Journal of Drug Targeting
2 publications, 2.41%
Heliyon
2 publications, 2.41%
Current Nanomedicine
2 publications, 2.41%
Communications Chemistry
1 publication, 1.2%
Livers
1 publication, 1.2%
Health Sciences Review
1 publication, 1.2%
Journal of Functional Biomaterials
1 publication, 1.2%
Chinese Chemical Letters
1 publication, 1.2%
Bioengineering
1 publication, 1.2%
Cancers
1 publication, 1.2%
Plasmonics
1 publication, 1.2%
Annales Pharmaceutiques Francaises
1 publication, 1.2%
Journal of Biomaterials Science, Polymer Edition
1 publication, 1.2%
Materials Today
1 publication, 1.2%
Recent Advances in Drug Delivery and Formulation
1 publication, 1.2%
Toxicon
1 publication, 1.2%
Nanoscale
1 publication, 1.2%
Emergent Materials
1 publication, 1.2%
Phytomedicine
1 publication, 1.2%
Polymers for Advanced Technologies
1 publication, 1.2%
1
2
3
4
5

Publishers

5
10
15
20
25
30
Elsevier
27 publications, 32.53%
MDPI
16 publications, 19.28%
Springer Nature
13 publications, 15.66%
Taylor & Francis
8 publications, 9.64%
Bentham Science Publishers Ltd.
7 publications, 8.43%
Wiley
5 publications, 6.02%
Royal Society of Chemistry (RSC)
1 publication, 1.2%
American Chemical Society (ACS)
1 publication, 1.2%
Pleiades Publishing
1 publication, 1.2%
Institute of Electrical and Electronics Engineers (IEEE)
1 publication, 1.2%
IntechOpen
1 publication, 1.2%
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.2%
Walter de Gruyter
1 publication, 1.2%
5
10
15
20
25
30
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
83
Share
Cite this
GOST |
Cite this
GOST Copy
Moghtaderi M. et al. Niosomes: a novel targeted drug delivery system for cancer // Medical Oncology. 2022. Vol. 39. No. 12. 240
GOST all authors (up to 50) Copy
Moghtaderi M., Sedaghatnia K., Bourbour M., Fatemizadeh M., Salehi Moghaddam Z., Hejabi F., Heidari F., Quazi S., Farasati Far B. Niosomes: a novel targeted drug delivery system for cancer // Medical Oncology. 2022. Vol. 39. No. 12. 240
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1007/s12032-022-01836-3
UR - https://doi.org/10.1007/s12032-022-01836-3
TI - Niosomes: a novel targeted drug delivery system for cancer
T2 - Medical Oncology
AU - Moghtaderi, Maryam
AU - Sedaghatnia, Kamand
AU - Bourbour, Mahsa
AU - Fatemizadeh, Mahdi
AU - Salehi Moghaddam, Zahra
AU - Hejabi, Faranak
AU - Heidari, Fatemeh
AU - Quazi, Sameer
AU - Farasati Far, Bahareh
PY - 2022
DA - 2022/09/29
PB - Springer Nature
IS - 12
VL - 39
PMID - 36175809
SN - 1357-0560
SN - 1559-131X
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Moghtaderi,
author = {Maryam Moghtaderi and Kamand Sedaghatnia and Mahsa Bourbour and Mahdi Fatemizadeh and Zahra Salehi Moghaddam and Faranak Hejabi and Fatemeh Heidari and Sameer Quazi and Bahareh Farasati Far},
title = {Niosomes: a novel targeted drug delivery system for cancer},
journal = {Medical Oncology},
year = {2022},
volume = {39},
publisher = {Springer Nature},
month = {sep},
url = {https://doi.org/10.1007/s12032-022-01836-3},
number = {12},
pages = {240},
doi = {10.1007/s12032-022-01836-3}
}